Biotechnology Market Research Reports

SEARCH REPORTS

Biotechnology Market Research Reports & Consulting

Biotechnology refers to the use of living organisms or their components, such as cells, enzymes, or genetic material, to develop or modify products, processes, or technologies for specific applications. It is a multidisciplinary field that combines biology, chemistry, genetics, and engineering to harness the power of biological systems for various purposes.

Biotechnology encompasses a wide range of applications, including healthcare, agriculture, industrial processes, and environmental sustainability. In healthcare, biotechnology plays a crucial role in the development of new drugs, therapies, and diagnostics. It involves techniques such as genetic engineering, recombinant DNA technology, and bioprocessing to produce pharmaceuticals, vaccines, and personalized medicine.

In agriculture, biotechnology is utilized for crop improvement, such as developing genetically modified organisms (GMOs) with enhanced traits like increased yield, resistance to pests or diseases, or improved nutritional content. It also involves techniques like tissue culture, marker-assisted breeding, and gene editing to improve plant and animal varieties.

Industrial biotechnology applies biological processes and organisms to produce biofuels, biochemicals, and biomaterials, offering more sustainable alternatives to conventional manufacturing processes. It involves using microorganisms or enzymes to convert renewable resources into valuable products.

Biotechnology also contributes to environmental sustainability by offering solutions for waste management, bioremediation, and renewable energy production. It can help in the cleanup of pollutants, the production of biofuels from biomass, and the development of sustainable materials.

Overall, biotechnology harnesses the inherent capabilities of living organisms and their genetic material to solve complex challenges and improve various aspects of human life, ranging from healthcare and agriculture to industrial and environmental applications.

Futuristic scope –

The field of biotechnology holds immense potential for future advancements and transformative changes in various areas. Here are some potential futuristic scopes of biotechnology:

Personalized Medicine: Biotechnology can enable the development of personalized medicine tailored to an individual's genetic makeup, lifestyle, and specific health needs. This may involve advanced genetic testing, gene therapies, and targeted drug delivery systems, leading to more effective and precise treatments.
Gene Editing and Gene Therapy: Continued advancements in gene editing technologies, such as CRISPR-Cas9, hold the promise of correcting genetic mutations responsible for inherited diseases. Gene therapies can potentially cure previously incurable genetic disorders by introducing healthy genes or modifying faulty ones.
Synthetic Biology: Synthetic biology involves designing and constructing new biological systems and organisms with desired functionalities. It may lead to the creation of novel materials, biofuels, and biochemicals, as well as the development of artificial organs and tissues for transplantation.
Agricultural Innovations: Biotechnology can contribute to enhancing crop productivity, improving nutritional content, and developing plants with enhanced resilience to climate change, pests, and diseases. This may involve advanced genetic engineering techniques, precision agriculture, and the use of bioinformatics for optimized crop management.
Microbiome Engineering: The human microbiome, consisting of trillions of microorganisms living in and on our bodies, has a significant impact on health and disease. Future biotechnology may involve engineering the microbiome to promote beneficial microbial communities, prevent or treat diseases, and improve overall well-being.
Bioinformatics and Big Data: With the increasing availability of genomic and biological data, bioinformatics plays a vital role in analyzing, interpreting, and deriving meaningful insights from large datasets. Integrating biotechnology with advanced computational methods can revolutionize drug discovery, disease diagnostics, and personalized healthcare.
Environmental Solutions: Biotechnology can contribute to environmental sustainability by developing eco-friendly alternatives to traditional industrial processes, bio-based materials, and renewable energy sources. Additionally, bioremediation techniques utilizing microorganisms can help clean up polluted environments and mitigate the impacts of human activities.
Neurobiology and Brain-Computer Interfaces: Advances in biotechnology may lead to a deeper understanding of the human brain and the development of brain-computer interfaces. This could enable enhanced communication between the brain and external devices, leading to breakthroughs in neuroprosthetics, neurorehabilitation, and cognitive enhancement.

It's important to note that while these futuristic scopes hold great potential, their realization will depend on continued research, ethical considerations, regulatory frameworks, and societal acceptance. Biotechnology is a rapidly evolving field, and the future may hold even more transformative possibilities beyond what we can currently envision.

Merger & Acquisition –

Merger and acquisition (M&A) activities are common in the biotechnology industry due to the dynamic nature of the sector, the need for research and development investments, and the potential for market consolidation. Biotechnology M&A deals typically involve the acquisition of one company by another, strategic partnerships, licensing agreements, or collaborations to gain access to new technologies, products, or intellectual property. Here are some key aspects and motivations behind biotechnology M&A:

Technology and Product Portfolio Expansion: Acquiring another biotechnology company can provide access to new technologies, research platforms, drug candidates, or product pipelines. It allows companies to broaden their offerings, diversify their portfolio, and strengthen their competitive position in the market.
Research and Development Capabilities: M&A activities often aim to enhance research and development capabilities by acquiring companies with complementary expertise, infrastructure, or proprietary platforms. This can accelerate the development of new drugs or therapies and shorten the time to market.
Intellectual Property and Patents: Acquiring companies with valuable intellectual property, patents, or proprietary technologies can provide a competitive advantage and enable market exclusivity for certain products. It can also protect against potential patent infringement lawsuits.
Market Access and Commercialization: Biotechnology companies may seek mergers or acquisitions to gain access to established distribution networks, marketing expertise, and regulatory pathways for product commercialization. This allows them to tap into new markets, expand their customer base, and increase revenue potential.
Synergies and Cost Savings: Merging with or acquiring another biotech company can generate synergies through the consolidation of operations, elimination of duplicate functions, and cost savings in areas such as manufacturing, supply chain, or administrative functions.
Talent and Expertise: M&A activities can provide access to skilled personnel, scientific talent, and experienced management teams. Acquiring companies may seek to retain key employees or leverage the expertise of the target company to drive future growth and innovation.
Competitive Landscape and Consolidation: The biotechnology industry is highly competitive, and M&A activities can be driven by a desire to consolidate market share, eliminate competitors, or establish dominant positions in specific therapeutic areas or technologies.

It's important to note that biotechnology M&A deals are subject to regulatory scrutiny, especially regarding antitrust considerations and potential impacts on competition. Additionally, the success of these deals depends on factors such as proper due diligence, integration planning, cultural alignment, and effective post-merger integration strategies.

Overall, biotechnology M&A activities are strategic maneuvers aimed at leveraging synergies, accessing new technologies or markets, and driving growth and competitiveness in a rapidly evolving industry.

Key segments in Biotechnology:

Biotechnology encompasses a wide range of applications and disciplines. Here are some key segments within the field of biotechnology:

Medical Biotechnology: This segment focuses on the application of biotechnology in healthcare, including the development of new drugs, therapies, diagnostics, and medical devices. It involves areas such as genetic engineering, gene therapy, regenerative medicine, personalized medicine, and biopharmaceutical production.
Agricultural Biotechnology: Agricultural biotechnology aims to improve crop productivity, quality, and sustainability through the use of genetically modified organisms (GMOs), molecular breeding techniques, and advanced biotechnological approaches. It includes areas such as crop improvement, genetic engineering, biopesticides, and agricultural biotechnology tools for precision farming.
Industrial Biotechnology: Industrial biotechnology involves using biological systems and processes to develop and produce industrial products. This segment focuses on the utilization of microorganisms, enzymes, and biocatalysts for the production of biofuels, biochemicals, bioplastics, and other renewable materials. It also includes bioremediation, waste management, and sustainable manufacturing processes.
Environmental Biotechnology: This segment applies biotechnological approaches to address environmental challenges and promote sustainability. It includes areas such as bioremediation, where microorganisms are used to degrade or remove pollutants from soil, water, and air. Additionally, environmental biotechnology involves wastewater treatment, renewable energy production, and the development of eco-friendly solutions for various industries.
Marine Biotechnology: Marine biotechnology focuses on the discovery and development of bioactive compounds, enzymes, and processes derived from marine organisms. It involves exploring marine biodiversity for potential applications in pharmaceuticals, cosmetics, nutraceuticals, and aquaculture.
Bioinformatics: Bioinformatics combines biology, computer science, and information technology to analyze and interpret biological data. It involves the development of computational tools, algorithms, and databases for genomics, proteomics, drug discovery, and systems biology research. Bioinformatics plays a crucial role in analyzing large datasets and deriving meaningful insights from biological information.

These segments are not mutually exclusive, and there is often overlap and collaboration among them. Many advancements and innovations in one segment can have implications and applications in others. The biotechnology field is continuously evolving, and new segments and interdisciplinary areas may emerge as scientific knowledge and technologies progress.

subsegments in Biotechnology:

Within the broader segments of biotechnology, there are several subsegments that focus on specific applications or disciplines. Here are some subsegments in biotechnology:

Therapeutic Biotechnology:

Gene Therapy: Development and delivery of genetic material to treat or prevent diseases by replacing or modifying faulty genes.
Cell Therapy: Use of cells, such as stem cells or immune cells, for treating diseases or regenerating damaged tissues.
Antibody Therapeutics: Development of monoclonal antibodies for targeted therapies and immunotherapy.
RNA-based Therapeutics: Utilization of RNA molecules, such as mRNA or RNAi, for therapeutic purposes.

Diagnostics and Personalized Medicine:

Molecular Diagnostics: Detection and analysis of genetic or molecular markers for disease diagnosis and monitoring.
Companion Diagnostics: Development of diagnostic tests to identify patients likely to respond to specific treatments.
Precision Medicine: Tailoring medical treatments to individual patients based on their genetic, environmental, and lifestyle factors.

Agricultural Biotechnology:

Crop Genetic Engineering: Modification of plant genomes to enhance traits like yield, resistance to pests/diseases, or nutritional content.
Molecular Breeding: Utilization of molecular markers and genomics to accelerate traditional breeding programs for crop improvement.
Seed Biotechnology: Development of improved seed varieties through genetic modification or tissue culture techniques.

Industrial Biotechnology:

Biofuels and Bioenergy: Production of biofuels, such as ethanol or biodiesel, from renewable biomass sources.
Enzyme Engineering: Design and optimization of enzymes for various industrial processes, including bio-based manufacturing.
Bioplastics and Biomaterials: Development of environmentally friendly alternatives to conventional plastics and materials.

Environmental Biotechnology:

Bioremediation: Use of microorganisms or plants to detoxify or remove pollutants from soil, water, and air.
Biofuels from Waste: Conversion of organic waste materials into biofuels through microbial fermentation or anaerobic digestion.
Environmental Monitoring: Application of biotechnology tools for monitoring and assessing environmental quality and biodiversity.

Bioinformatics and Computational Biology:

Genomics and Proteomics: Analysis and interpretation of genomic and proteomic data using computational approaches.
Drug Discovery and Design: Utilization of computational methods to identify and design potential drug candidates.
Systems Biology: Integration of biological data and modeling to understand complex biological systems.

These subsegments represent specific areas of focus within biotechnology, highlighting the diverse applications and disciplines within the field. Advances in each subsegment contribute to the overall progress and impact of biotechnology on various industries and sectors.

Biotechnology eco-system:

Biotechnology Industry Ecosystem: The biotechnology industry ecosystem consists of a complex network of interconnected stakeholders, including biotechnology companies, research institutions, regulatory bodies, investors, healthcare providers, and patients. Biotechnology companies serve as the core entities driving innovation, developing new technologies, and bringing novel products to market. Research institutions play a crucial role in advancing scientific knowledge, conducting preclinical and clinical studies, and collaborating with industry partners. Regulatory bodies establish guidelines and regulations to ensure safety, efficacy, and ethical standards in biotechnology applications. Investors provide funding and financial support to fuel research and development efforts. Healthcare providers adopt and utilize biotechnological advancements in diagnosing and treating diseases, while patients benefit from innovative therapies and personalized medicine. Collaboration, knowledge-sharing, and a supportive regulatory framework are essential for fostering a vibrant biotechnology ecosystem that can address global challenges and improve human well-being.
Agricultural Biotechnology Ecosystem: The agricultural biotechnology ecosystem encompasses a network of stakeholders dedicated to improving crop productivity, sustainability, and food security. Seed companies and agricultural biotechnology firms are at the forefront, employing genetic engineering, molecular breeding, and biotechnological tools to develop genetically modified crops with enhanced traits. Research institutions and universities conduct studies to understand plant genetics, develop innovative techniques, and train future experts. Farmers and growers play a vital role in implementing and adopting biotechnology solutions in their fields. Regulatory agencies establish guidelines for the safe and responsible use of genetically modified organisms in agriculture. Consumer acceptance and engagement, along with public-private partnerships, shape the agricultural biotechnology ecosystem by ensuring transparent communication and addressing societal concerns related to GMOs and food production.
Industrial Biotechnology Ecosystem: The industrial biotechnology ecosystem encompasses a network of stakeholders focused on utilizing biological systems for sustainable manufacturing processes and the production of renewable materials. Biotechnology companies develop and optimize biological processes and enzymes for the production of biofuels, biochemicals, and bioplastics. Academic and research institutions contribute to scientific advancements and provide expertise in bioengineering and bioprocessing. Government bodies establish policies and incentives to support the growth of the bioeconomy. Investors and venture capitalists provide funding and financial resources to scale up and commercialize biotechnological innovations. Collaboration between industry players, regulatory agencies, and research institutions is essential for knowledge exchange, technology transfer, and driving the adoption of bio-based solutions in various industries.
Healthcare Biotechnology Ecosystem: The healthcare biotechnology ecosystem involves a diverse range of stakeholders dedicated to improving human health and well-being through biotechnological advancements. Biotechnology companies engage in research and development of innovative drugs, therapies, and diagnostics. Academic and research institutions conduct preclinical and clinical studies, contributing to scientific knowledge and evidence-based medicine. Regulatory bodies play a critical role in ensuring safety, efficacy, and ethical standards in drug development and medical devices. Healthcare providers, including hospitals, clinics, and medical professionals, adopt and utilize biotechnological innovations to diagnose, treat, and manage diseases. Patients and patient advocacy groups provide insights, feedback, and support in shaping research priorities and treatment outcomes. Collaboration among stakeholders, including public-private partnerships, is essential for translating scientific discoveries into practical applications, ensuring access to innovative therapies, and addressing healthcare challenges.

These ecosystems demonstrate the interconnectedness of various stakeholders involved in different aspects of biotechnology, working together to drive innovation, address global challenges, and improve human health, agriculture, industry, and the environment.

Top players:

The field of biotechnology is populated by numerous prominent players, ranging from established multinational companies to emerging startups. While it is challenging to provide an exhaustive list, here are some well-known and influential companies in the biotechnology sector:

Johnson & Johnson: A multinational healthcare company that operates in various sectors, including pharmaceuticals, medical devices, and consumer health. It is involved in the development of innovative drugs and therapies across a range of therapeutic areas.
Roche Holding AG: A Swiss multinational healthcare company known for its expertise in pharmaceuticals and diagnostics. Roche focuses on developing and manufacturing drugs for cancer, autoimmune diseases, and other critical medical conditions.
Novartis International AG: A global pharmaceutical company with a diverse portfolio of drugs, including innovative therapeutics for oncology, ophthalmology, immunology, and other disease areas. Novartis is also engaged in gene and cell therapies.
Amgen Inc.: A biotechnology company specializing in the development of innovative therapies for various diseases, including cancer, cardiovascular diseases, and neurological disorders. Amgen is known for its expertise in biologics and biosimilars.
Gilead Sciences Inc.: A research-based biopharmaceutical company focusing on the development and commercialization of therapies for HIV/AIDS, hepatitis, oncology, and other areas of unmet medical need.
Moderna Inc.: A leading mRNA therapeutics company that gained significant attention for its role in developing and manufacturing COVID-19 vaccines. Moderna is actively involved in advancing mRNA-based therapies for various diseases.
Biogen Inc.: A biotechnology company specializing in neurological diseases, with a focus on developing therapies for conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy.
Regeneron Pharmaceuticals Inc.: Known for its innovative monoclonal antibody therapies, Regeneron develops treatments for conditions such as age-related macular degeneration, cancer, and inflammatory diseases.

CRISPR Therapeutics AG: A gene-editing company that utilizes CRISPR-Cas9 technology for developing potential therapies for genetic disorders, cancer, and other diseases.
Vertex Pharmaceuticals Inc.: A biopharmaceutical company focusing on the development of drugs for cystic fibrosis and other serious diseases, using its expertise in small molecule drug discovery and precision medicine.

It's worth noting that the biotechnology landscape is highly dynamic, and the prominence of companies can change over time due to mergers, acquisitions, and the emergence of new players. The listed companies represent a snapshot of some influential players as of my knowledge cutoff in September 2021, and it is recommended to refer to the latest industry updates and reports for a comprehensive understanding of the current top players in biotechnology.

High grown opportunities:

The field of biotechnology offers a range of high-growth opportunities driven by technological advancements, market demands, and societal needs. Here are some areas that present significant growth potential in biotechnology:

Gene and Cell Therapies: The development of gene therapies and cell-based therapies holds immense promise for treating genetic disorders, cancer, and other complex diseases. Advancements in gene editing technologies like CRISPR-Cas9 and the emergence of CAR-T cell therapies have opened up new avenues for personalized medicine and targeted therapies.
Precision Medicine: The shift towards personalized medicine, which tailors treatment based on an individual's genetic makeup, is driving growth in the biotechnology sector. The integration of genomics, molecular diagnostics, and bioinformatics enables the identification of biomarkers, optimizing treatment outcomes, and reducing adverse effects.
Biopharmaceuticals: The market for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilars, continues to expand rapidly. Biotechnology companies are developing innovative biologic drugs for various diseases, such as cancer, autoimmune disorders, and rare genetic conditions.
Synthetic Biology: The convergence of biology, engineering, and computer science has given rise to synthetic biology, which involves designing and constructing new biological parts, devices, and systems. Synthetic biology offers opportunities in biofuel production, biochemical manufacturing, and sustainable agriculture, among other areas.
Agricultural Biotechnology: With the global population expected to reach nearly 10 billion by 2050, there is a growing need for sustainable and efficient agricultural practices. Agricultural biotechnology plays a vital role in developing genetically modified crops with improved yields, resistance to pests and diseases, and enhanced nutritional content.
Digital Health and Wearable Devices: The integration of biotechnology with digital health technologies and wearable devices has the potential to transform healthcare delivery and patient monitoring. Remote patient monitoring, telemedicine, and data-driven insights enable personalized healthcare, disease prevention, and improved management of chronic conditions.
Microbiome Research: The study of the human microbiome, consisting of the microorganisms that inhabit our bodies, has gained significant attention. Understanding the role of the microbiome in health and disease opens up opportunities for developing microbiome-based therapeutics, diagnostics, and personalized nutrition.
Bioinformatics and Data Analytics: The exponential growth of biological data requires advanced computational tools and algorithms for data analysis and interpretation. Bioinformatics, data analytics, and artificial intelligence (AI) are crucial for deriving meaningful insights from genomics, proteomics, and clinical data, driving innovation in drug discovery, precision medicine, and personalized healthcare.
Environmental Biotechnology: The increasing focus on sustainability and environmental preservation offers opportunities for biotechnology applications in areas such as bioremediation, waste management, renewable energy production, and eco-friendly industrial processes.
Nanobiotechnology: The convergence of nanotechnology and biotechnology has led to advancements in drug delivery systems, diagnostic tools, and nanoscale imaging techniques. Nanobiotechnology holds promise for targeted drug delivery, early disease detection, and innovative therapeutics.

These are just a few examples of the high-growth opportunities within the broad field of biotechnology. As technology evolves and scientific knowledge expands, new opportunities will continue to emerge, creating an exciting and dynamic landscape for biotechnology innovation and entrepreneurship.

Challenges in Biotechnology Industry

The biotechnology industry faces several challenges that impact research, development, commercialization, and the overall growth of the sector. Some of the key challenges include:

Scientific and Technical Complexity: Biotechnology involves cutting-edge scientific advancements and complex technologies. Developing new therapies, understanding biological mechanisms, and conducting clinical trials require significant scientific expertise and resources. Overcoming scientific challenges and translating discoveries into practical applications can be time-consuming and resource-intensive.
Regulatory and Compliance Hurdles: Biotechnology products, especially those involving gene therapies and genetically modified organisms, face rigorous regulatory scrutiny. Compliance with strict regulations, such as those related to safety, efficacy, and ethical considerations, adds complexity and time to the development and commercialization process. Navigating through complex regulatory pathways and ensuring compliance can be challenging for biotechnology companies.
Cost of Research and Development: The cost of research and development (R&D) in biotechnology is substantial. Developing new drugs, therapies, and technologies involves extensive preclinical and clinical trials, which can be expensive and time-consuming. Many potential treatments do not reach the market due to high R&D costs, low success rates, and stringent regulatory requirements.
Intellectual Property Protection: Intellectual property (IP) protection is crucial in the biotechnology industry to safeguard innovations and secure market exclusivity. However, obtaining and defending patents for biotechnological inventions can be challenging due to the complex nature of the technologies involved and the potential for overlapping IP rights. IP disputes and challenges can impact the commercial viability of biotechnology products and hinder innovation.
Market Access and Reimbursement: Bringing biotechnology products to market and ensuring access to patients can be challenging. Negotiating pricing, securing reimbursement from healthcare systems, and demonstrating value and cost-effectiveness are critical considerations. Market access barriers, including formulary restrictions and pricing pressures, can impact the adoption and commercial success of biotechnological innovations.
Ethical and Societal Concerns: Biotechnology raises ethical and societal concerns, particularly in areas such as gene editing, genetically modified organisms, and privacy issues related to genetic data. Balancing scientific progress with ethical considerations, public perception, and societal acceptance is an ongoing challenge for the biotechnology industry.
Talent and Skills Gap: The biotechnology sector requires highly skilled professionals with expertise in diverse areas such as biology, bioinformatics, engineering, and regulatory affairs. However, there is often a shortage of qualified talent in specialized fields, leading to a skills gap and intense competition for skilled professionals.
Funding and Investment Risks: Biotechnology companies heavily rely on external funding, including venture capital, government grants, and partnerships. Securing funding for R&D, clinical trials, and commercialization can be challenging, especially for early-stage companies. The high risk and long timelines associated with biotechnology investments can make it difficult to attract and retain investors.
Market Uncertainty and Competition: The biotechnology industry operates in a competitive and rapidly evolving market. Market dynamics, including changing healthcare policies, regulatory shifts, and evolving competitive landscapes, can impact product demand and market access. Staying ahead of the competition and adapting to market changes require agility and strategic decision-making.
Manufacturing and Scale-up Challenges: Scaling up biotechnological processes from lab-scale to commercial production can pose significant challenges. Manufacturing consistency, cost-effectiveness, and maintaining product quality are crucial for successful commercialization. Developing efficient manufacturing processes and ensuring scalability are critical hurdles for biotechnology companies.

Addressing these challenges requires collaboration among industry stakeholders, continuous investment in research and development, supportive regulatory frameworks, and a favorable business environment. Overcoming these hurdles will enable the biotechnology industry to realize its full potential and continue driving innovation and positive impact in healthcare, agriculture, industry, and other sectors.

High CAGR geography

Several geographic regions are experiencing significant growth in the field of biotechnology, demonstrating high Compound Annual Growth Rates (CAGR) in biotechnology-related activities. Some of the notable regions with high CAGR in biotechnology include:

Asia-Pacific: The Asia-Pacific region, including countries like China, India, and South Korea, has witnessed remarkable growth in the biotechnology sector. Factors such as a large population, increasing investments in research and development, supportive government policies, and a growing focus on healthcare and agriculture contribute to the high CAGR in this region. Rising biopharmaceutical manufacturing capabilities, expansion of contract research organizations, and advancements in regenerative medicine and gene editing technologies are driving the growth of biotechnology in Asia-Pacific.
North America: North America, particularly the United States, remains a dominant player in the biotechnology industry. With a strong emphasis on research and development, significant investments in biotechnology startups, and a supportive regulatory environment, the region continues to experience substantial growth. The presence of major biotechnology companies, renowned research institutions, and a well-established venture capital ecosystem contribute to the high CAGR in North America. Areas such as gene and cell therapies, precision medicine, and synthetic biology are witnessing notable advancements in the region.
Europe: Europe is a key region for biotechnology innovation and commercialization. Countries such as Germany, the United Kingdom, and Switzerland have robust biotechnology ecosystems characterized by academic excellence, technological advancements, and well-established biotech clusters. Europe demonstrates high CAGR in areas such as pharmaceutical biotechnology, industrial biotechnology, and agricultural biotechnology. Supportive regulatory frameworks, government funding, and collaborations between academia and industry drive the growth of biotechnology in Europe.
Latin America: Latin America has emerged as a region with growing biotechnology potential. Countries like Brazil, Mexico, and Argentina are witnessing increased investments in biotechnology research, development, and manufacturing. The region has significant biodiversity, offering opportunities for pharmaceutical research, agricultural biotechnology, and environmental biotechnology. Government initiatives, public-private partnerships, and the presence of skilled researchers contribute to the high CAGR in biotechnology in Latin America.
Middle East and Africa: The Middle East and Africa region are experiencing a rising interest in biotechnology and its applications. Countries like United Arab Emirates, Israel, and South Africa are at the forefront of biotechnology development in the region. Investments in healthcare infrastructure, growing pharmaceutical markets, and a focus on agricultural innovation contribute to the high CAGR in biotechnology. The region also shows potential in areas such as biopharmaceutical production, genetic diagnostics, and bioinformatics.

It's important to note that the CAGR in biotechnology can vary within specific countries and regions, depending on factors such as local infrastructure, regulatory frameworks, funding availability, and market demands. Additionally, emerging markets in other regions, such as Africa and Southeast Asia, are also poised for growth and may demonstrate high CAGR in the biotechnology sector in the coming years.

see less

Market Reports

Hydrophobic Interaction Chromatography Market by Product & Services (Resin, Columns (Empty, Prepacked), Buffer), Sample (Monoclonal Antibodies, Vaccines), End User (Pharmaceutical Companies, CROs & CMOs, Research Institutes) - Global Forecast to 2023

The global hydrophobic interaction chromatography market is projected to reach USD 418.2 million in 2023 from USD 271.0 million in 2017, at a CAGR of 7.5%. The base year considered for the study is 2017, and the forecast for the market size is provided for the period between 2018 and 2023. In the current market scenario, there is a growing demand for hydrophobic interaction chromatography. The major factors driving the growth of this market are the increasing demand for monoclonal antibodies and increasing R&D expenditure in biopharmaceuticals. The key players in the global hydrophobic interaction chromatography market are GE Healthcare (US), Bio-Rad Laboratories (US), Sartorius (Germany), and Thermo Fisher Scientific (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
Protein Binding Assays Market by Technology (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization) - Global Forecast to 2023

The major players operating in the global protein binding assay market are Thermo Fisher (US), HTDialysis (US), Merck (US), GE Healthcare (US), and Absorption Systems (US). The global protein binding market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at a CAGR of 10.7%. The growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure are driving the growth of this market. The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany).
- Published: August 2018
- Price: $ 4950
- TOC Available:
Microarray Analysis Market by Product & Service (Consumables, Instrument, Software, Services), Type (DNA, Protein Microarray), Application (Research), End User (Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies) - Global Forecasts to 2023

The global microarray analysis market is projected to reach USD 5.52 billion by 2023, at a CAGR of 7.6%. The major factors driving the growth of this market are the increasing incidence of cancer, increasing funding for genomic and proteomic research, and growing application areas of microarrays. Key players in the microarray analysis market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Molecular Devices (US), PerkinElmer Inc. (US), Illumina, Inc. (US), GE Healthcare (US), and Bio-Rad Laboratories Inc. (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
Transfer Membrane Market by Type (PVDF, Nitrocellulose, Nylon), Transfer Method (Tank, Semi-dry, Dry), Application (Western, Northern, Southern Blot, Protein Sequencing), End user (Academia, Diagnolab, Pharmaceutical Companies) - Global Forecast to 2023

The global transfer membrane market is expected to reach USD 187.9 million by 2023 from USD 174.8 million in 2018, at a CAGR of 1.5% during the forecast period. Factors such as increasing public and private funding for life science research, the significantly high prevalence of target diseases across the globe, and increasing R&D spending by pharmaceutical and biotechnology companies are expected to drive the growth of transfer membrane market. The key players in the transfer membrane market include Merck KGaA (US), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), GE Healthcare (US), PerkinElmer (US), Pall Coporation (US), Advansta (US), GVS (Italy), Santa Cruz Biotechnology (US), Abcam (UK), ATTO Corporation (Japan), Carl Roth (Germany), Macherey-Nagel (Germany), Azure Biosystems (US), and Axiva Sichem Biotech (India), among others.
- Published: June 2018
- Price: $ 4950
- TOC Available:
Creatinine Measurement Market by Product (Kits, Reagents), Test Type (Jaffe method, Enzymatic creatinine method), Sample (Serum Creatinine, Urine) and End User (Hospitals, Diagnostic Laboratories), Region (North America, Europe) - Global Forecasts to 2023

The global creatinine measurement market is projected to reach USD 564.5 Million by 2023, at a CAGR of 8.4%. The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives. The creatinine measurement market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include F. Hoffmann-la Roche Ltd (Switzerland)., Abbott Laboratories (US), Danaher Corporation (US), Thermo Fisher Scientific Inc (US), Siemens Healthineers (Germany), Randox Laboratories (UK)., Pointe Scientific, Inc (US), Sentinel Ch. Spa. (Italy), Diasys Diagnostic Systems GmbH (Germany), Dialab GmbH (Vienna), Diazyme Laboratories, Inc (US), Wako Pure Chemical Industries, Ltd. (Japan), Ortho Clinical Diagnostics (US), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China).
- Published: June 2018
- Price: $ 4950
- TOC Available:
Gene Panel Market by Product & Service, Technique (Amplicon, Hybridization), Design (Predesign, Custom), Application (Cancer, Congenital Disease, Pharmacogenetics) & End User (Hospital, Research Center, Pharmaceutical Companies) - Global Forecasts to 2023

The global gene panel market is expected to reach USD 2.95 Billion by 2023, at a CAGR of 19.2%. The growth of this market is mainly driven by the increasing prevalence of chronic diseases, growing company initiatives, and rising adoption of gene panel owing to the benefits they offer. The gene panel market is fragmented, with the presence of several large as well as emerging players. Prominent players in the gene panels market include Illumina, Inc. (US), BGI (China), Agilent Technologies (US), Eurofins Scientific (US), QIAGEN (Germany), GENEWIZ, Inc. (US), Novogene Corporation (China), Personalis (US), Thermo Fisher Scientific (US), F. Hoffmann-La Roche AG (Switzerland), Integrated DNA Technologies (IDT) (US), GATC Biotech AG (GATC Biotech) (Germany), and ArcherDx (US). Players in this market are adopting various organic and inorganic strategies, such as product launches & upgradations, agreements, partnerships, joint ventures, collaborations, and acquisition to widen their product portfolios and expand their presence in the market.
- Published: May 2018
- Price: $ 4950
- TOC Available:
Specimen Validity Testing Market by Product (Reagent, Controls, Assay Kits, Disposables), Type (Laboratory, POC Testing), End User (Workplace, Drug Screening, Pain Management, Drug Rehabilitation Centers) - Global Forecast to 2023

The global specimen validity testing market is projected to reach USD 1.49 Billion by 2023 from USD 1.10 Billion in 2018, at a CAGR of 6.3%. The growth of the market is primarily driven by the growth in drug screening market and increase in workplace drug testing. While the specimen validity testing market represents significant growth opportunities, market growth may be hindered due to the emergence of alternative drug screening tests. The specimen validity testing market is marked by the presence of several big and small players. Prominent players offering specimen validity testing products include Thermo Fisher Scientific (US), Sciteck, Inc. (US), American Bio Medica Corporation (ABMC), Alere [now a part of Abbott (US)], Express Diagnostics Int'l, Inc. (US), and Premier Biotech, Inc. (US). While, Laboratory Corporation of America Holdings (LabCorp) (US), Quest Diagnostics (US), Alere Toxicology (Alere) (US), ACM Global Laboratories (US), Clinical Reference Laboratory (CRL) (US), SureHire (Canada), and CannAmm (Canada) are some of the leading service providers.
- Published: May 2018
- Price: $ 4950
- TOC Available:
Neuroscience Antibodies & Assays Market by Product (Reagent (Media, Sera, Stain, Enzymes, Probe), Instruments), Technology (Immunoassay (Elisa), Molecular Diagnostics), Application (IVD) & End User (Research Institute, Hospital) - Global Forecast to 2023

The global neuroscience antibodies and assays market is expected to reach USD 4.18 Billion by 2023, at a CAGR of 10.2%. Growth in this market is driven by the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries. The neuroscience antibodies and assays market is fragmented, with the presence of several large as well as emerging players. Some of the the top players in this market are Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany).
- Published: May 2018
- Price: $ 4950
- TOC Available:
Stem Cell Banking Market by Source (PSC, BMSC, ADSC, hESC, DPSC, NSC), Service Type (Sample Processing, Analysis, Collection, Storage), Application (Personalized Storage, Clinical (Autoimmune, Hematopoietic Disorders), Research) - Global Forecasts to 2023

The global stem cell banking market is projected to reach USD 9.30 Billion by 2023, at a CAGR of 8.2%. Major players in the global stem cell banking market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).
- Published: May 2018
- Price: $ 4950
- TOC Available:
In Vitro Lung Model Market by Type (2D, 3D (In-house, Commercial)), Application (Drug Screening, Toxicology, 3D Model Development, Basic Research, Physiologic Research, Stem Cell Research, Regenerative Medicine) - Global Forecasts to 2023

The lung in vitro models market is projected to reach USD 427.4 Million by 2023, at a CAGR of 17.5%. The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, advancements in Cell Culture technologies, and the development of new 3D in vitro models. The major players in the Lung in vitro models market include Epithelix (Switzerland), MatTek Corporation (US), Lonza (Switzerland), ATCC (US), InSphero (Switzerland), Emulate (US), AlveoliX (Switzerland), Oncotheis (Switzerland), Insphero (Switzerland), TissUse (Switzerland), Mimetas (Netherlands), and CN Bio Innovations (UK).
- Published: April 2018
- Price: $ 11000
- TOC Available:
Creatinine Assay Kits Market by Type (Jaffe's Kinetic Test, Creatinine-PAP, and ELISA), Sample (Blood, Serum, Urine, Saliva, CSF, Tissue Homogenate, Sweat) and Region (North America, Europe, Asia and RoW) - Global Forecast to 2022

The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding. The creatinine assay kits market is highly fragmented with the presence of several large as well as emerging players. Prominent players in this market include Thermo Fisher Scientific (US), Merck (Germany), Abbott Laboratories (US), Abcam (UK), Quidel (US), Enzo Life Sciences (US), Cayman Chemical (US), Crystal Chem (US), Cell Biolabs (US), Genway Biotech (US), BioAssay Systems (US), Wako Pure Chemical Industries (Japan), Tulip Diagnostics (India), BioVision (US), and Arbor Assays (US).
- Published: March 2018
- Price: $ 14000
- TOC Available:
Cell Harvesting Market by Type (Manual, Automated), Application (Biopharmaceutical, Stem Cell Research), End User (Biotechnology, Biopharmaceutical Companies, Research Institute), and Region (North America, Europe, APAC, Row) - Global Forecasts to 2023

The global cell harvesting market is expected to reach USD 324.5 Million by 2023, at a CAGR of 8.7%. Some of the major players operating in the cell harvesting market are PerkinElmer (US), Brandel (US), TOMTEC (US), Cox Scientific (UK), Connectorate (Switzerland), Scinomix (US), ADSTEC (Japan), and Terumo BCT (a part of Terumo Corporation) (Japan).
- Published: March 2018
- Price: $ 4950
- TOC Available:
Thyroid Function Test Market by Type (TSH Tests, T4 Tests, T3 Tests), End User (Hospitals, Diagnostic Laboratories, Research Laboratories & Institutes), and Region (North America, Europe, APAC, LATAM, and MEA)

The global thyroid function test market is expected to grow at a CAGR of 5.9%. This growth can be attributed to factors such as increasing incidence of thyroid disorders, increasing awareness about thyroid disorders, increasing prevalence of lifestyle diseases, rising geriatric population, and increasing consumption of alcohol and tobacco. The prominent players in the global thyroid function tests market include Thermo Fisher (US), Abbott (US), Roche (Switzerland), DiaSorin (Italy), Danaher (US), Kronus (US), Merck (Germany), Cortez Diagnostics (US), bioMérieux (France), Qualigen (US), and Autobio Diagnostics (China).
- Published: February 2018
- Price: $ 4950
- TOC Available:
Next-Generation Sequencing (NGS) Services Market by Type (Targeted, RNA-Seq, Exome, De Novo), Technology (Sequencing by Synthesis, Ion semiconductor, SMRT, Nanopore), & Application (Diagnostics, Oncology, Drug Discovery, Agriculture) - Forecasts to 2022

The global next-generation sequencing (NGS) services market is projected to reach USD 2,748.6 Million by 2022 from USD 1,059.2 Million in 2017; growing at a CAGR of 21.0%. As of 2016, the major NGS services providers in the global NGS services market included BGI (China), Eurofins Scientific SE (Luxembourg), PerkinElmer, Inc. (U.S.), QIAGEN (Germany), Macrogen Inc. (South Korea), GENEWIZ, Inc. (U.S.), Illumina, Inc. (U.S.), Novogene Corporation (China), GATC Biotech AG (Germany), DNA Link, Inc (South Korea), Genotypic Technology Pvt Ltd (India), LGC Limited (U.K.), Wuxi Apptech Co. Ltd. (China), Zymo Research Corp (U.S.), Source BioScience (U.K.), and Personalis, Inc. (U.S.) among others.
- Published: August 2017
- Price: $ 4950
- TOC Available:
Competent Cells Market by Type (Chemically, Electrocompetent), Application (Subcloning, Phage Display Library Production, Unstable DNA Cloning, High-Throughput Cloning, Mutagenesis), End User (Pharmaceutical Companies, Academia) and Region

The competent cells market is expected to grow at a CAGR of 10.2% from 2017 to 2022. Key players operating in the competent cells market include Merck KGaA (Germany), Promega Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S), New England Biolabs (U.S.), Takara Bio (Japan), Agilent Technologies (U.S.), Lucigen (Epicenter) (Illumina) (U.S.), QIAGEN N.V. (Germany), OriGene Technologies (U.S.), Bioline (U.K.), Zymo Research (U.S.), Beijing TransGen Biotech Co., Ltd. (China), Source BioScience (U.K.), IBA GmBH (Germany), Genewiz (U.S.), BioDynamics Laboratory, Inc. (Japan), GCC Biotech (India), SMOBIO Technology (Taiwan), GeneScript Corporation (U.S.), Bio-Rad Laboratories (U.S.), Life Technologies (India) Pvt. Ltd., Cell Applications, Inc. (U.S.), Delphi Genetics (Belgium), Scarab Genomics, LLC (U.S.), and Yeastern Biotech Co., Ltd. (Taiwan).
- Published: July 2017
- Price: $ 4950
- TOC Available:
Cellular Health Screening Market by Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs), and Region

The global cellular health screening market is expected to grow at a CAGR of 10.0% during the forecast period. The global cellular health screening market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.).
- Published: July 2017
- Price: $ 9500
- TOC Available:
Protein Assays Market by Product (Reagent, Kit, Instruments), Type (Dye Binding, Test Strip), Application (Drug Discovery, Disease Diagnosis), Technology (Colorimetric, Fluorescence), End User (Pharmaceutical, Clinical Lab) - Global Forecasts to 2022

The protein assays market is projected to reach USD 2.41 Billion by 2022, at a CAGR of 11.1%. Some of the prominent players in the market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).
- Published: May 2017
- Price: $ 4950
- TOC Available:
Cell Signaling Market by Type (Endocrine, Paracrine), Pathway (Akt, AMPK, Hedgehog, Notch), Product (Consumables, Instruments), Technology (Flow Cytometry, ELISA, Mass Spectrometry) & Application (Research, Cancer, Immunology) - Global Forecast to 2022

The cell signaling market is projected to reach USD 3.51 Billion by 2022 from USD 2.53 Billion in 2017, at a CAGR of 6.8%. The term “cell signaling” is used to define the complex interactive system of signals that regulates and mediate various cellular responses in the human body.
- Published: May 2017
- Price: $ 4950
- TOC Available:
High-Resolution Melting Analysis Market by Product (Supermix Reagent, RT PCR Instrument, Software), Application (SNP Genotyping, Mutation Discovery, Epigenetics), Enduser (Research Laboratories, Hospital, Diagnostic Center) - Global Forecast to 2021

The global high-resolution melting analysis market is projected to grow at a CAGR of 3.1%. Rising prevalence of infectious diseases and genetic disorders; increasing public-private investments, funds, and grants for research on genetic analysis technologies; and advantages of HRM over other genotyping technologies are the major factors driving market growth.
- Published: April 2017
- Price: $ 4950
- TOC Available:
High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022

The global high-content screening market is projected to reach USD 909.0 Million by 2022 at a CAGR of 10.3% during the forecast period. The factors expected to drive the growth of the market are growth in funding for cellular research, cost containment in pharma R&D, and technological advancements in HCS solutions. The rapid growth in developing countries across APAC is also expected to provide an opportunity for revenue generation in the market. However, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of the instruments are expected to restrain the market growth.
- Published: April 2017
- Price: $ 4950
- TOC Available:
High Throughput Process Development Market by Product (Consumables (Minicolumn, Mini Bioreactor), Instruments), Services, Software, Molecule Type (mAB), Technology (Affinity Chromatography), End User (Biopharmaceutical) - Global Forecast to 2021

The global high throughput process development market is expected to reach USD 415.5 Million in 2021 from USD 212.1 Million in 2016, at a CAGR of 14.4% from 2016 to 2021. Major players operating in the high throughput process development market include Danaher (US), GE Healthcare (US), Agilent Technologies (US), Merck Millipore (Germany), and Thermo Fisher Scientific (US).
- Published: April 2017
- Price: $ 4950
- TOC Available:
Downstream Processing Market by Technique (Separation, Concentration, Purification), Product (Chromatography Column & Resin, Filter, Single use), Application (Mab Production), End User (Contract Manufacturing Organization) - Global Forecast to 2021

The global downstream processing market is projected to grow at a CAGR of 16.4%. In this report, the global downstream processing market is broadly segmented on the basis of technique, product, application, end user, and region.
- Published: March 2017
- Price: $ 4950
- TOC Available:
Top 10 Bioprocess Technology Market by Cell Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, Biologics Safety Testing, Tangential Flow Filtration, Virus Filtration & Region - Forecast to 2021

The global top 10 bioprocess technology market is expected to USD 71.03 Billion by 2021 from USD 39.30 Billion in 2016, at a CAGR of 12.4% between 2016 and 2021. Growth in the biopharmaceutical industry, increase in R&D spending, rising demand for vaccine production, and technological advancements form important growth drivers for this market. On the other hand, stringent regulatory policies and high cost of instruments are restraining market growth for bioprocess technologies.
- Published: January 2017
- Price: $ 4950
- TOC Available:
Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021

The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.
- Published: January 2017
- Price: $ 4950
- TOC Available:
Transfection Reagents and Equipment Market by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral)), Application (Biomedical, Protein Production), End User - Global Forecast to 2021

The global transfection reagents and equipment market is projected to grow at a CAGR of 7.5%. This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer. Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.
- Published: January 2017
- Price: $ 4950
- TOC Available:
Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021

The global rat model market is projected to grow at a CAGR of 8.7%. Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.
- Published: January 2017
- Price: $ 4950
- TOC Available:
Cell Sorting Market by Technology (FACS-based Droplet Sorting, MACS, Microfluidics), Product (Cell Sorters, Reagents, Consumables), Application (Research, Clinical), End User (Research Institutes, Biopharma Companies, Medical Schools) - Forecasts to 2021

The global cell sorting market is projected to grow at a CAGR of 7.0%. Factors such as technological advancements in cell sorters, rising funding and investments for development of technologically advanced cell sorters, and growing adoption of cell sorting techniques in research activities are driving the growth of this market. The market is further driven by factors such as the growing prevalence of HIV/AIDS and cancer, expanding pharmaceutical and biotechnology industries, and launch of specific reagents for specific applications. However, factors such as the high cost of instruments and lack of awareness & technical knowledge regarding the use of cell sorters are hampering the growth of this market.
- Published: January 2017
- Price: $ 4950
- TOC Available:
PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies)

The global PEGylated proteins market size is projected to grow at a CAGR of 10.5%. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
Bioreactors Market by Scale Range (20L, 1500L), Material (Single-Use, Stainless Steel), Usage (Lab Scale, Pilot Scale, Full Scale), Suppliers (OEMs, EPCs), End-User (R&D Departments, Biopharmaceutical Manufacturers), Region

The global bioreactors market size is projected to grow at a CAGR of 6.8%. The increase in adoption of single-use technologies, use of hybrid technologies: single-use and stainless steel, growing popularity of single-use bioreactor among biopharmaceutical companies, and growing biologics are spurring the growth of the bioreactors market. However, regulatory concerns related to single-use bioreactors, issues regarding leachable and extractable related to single-use bags is hampering the growth of this market.
- Published: September 2016
- Price: $ 18000
- TOC Available:
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics)

The global cancer immunotherapy market size is projected to grow at a CAGR of 14.0%. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market.
- Published: September 2016
- Price: $ 4950
- TOC Available:
Antibody Production Market by Process (Upstream Processing, Downstream Processing, and Filtration), End-User (Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, and Research Institutes)

The global antibody production market size is projected grow at a CAGR of 12.3%. The market is segmented on the basis of process and end users. By process, the market is segmented into upstream processing, downstream processing, and filtration.
- Published: August 2016
- Price: $ 4950
- TOC Available:
Plasma Therapy Market by Type (Pure PRP, Leukocyte-Rich PRP, Pure Platelet-Rich Fibrin, Leukocyte-Rich Fibrin), Source (Autologous, Allogenic), Application (Orthopedic, Dermatology, Cardiac Muscle Injury), End User, Region - Global Forecast to 2021

The global plasma therapy market is expected to grow from USD 135.6 Million in 2016 to USD 297.6 Million by 2021, at a CAGR of 14.0% from 2016 to 2021. Factors driving the growth of the plasma therapy market include rising incidences of trauma and increasing healthcare expenditure worldwide.
- Published: July 2016
- Price: $ 4950
- TOC Available:
Viral Inactivation Market by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs) - Global Forecast to 2021

The global viral inactivation market is segmented on the basis of method, product, application, end user, and geography. By method, the market is divided into solvent detergent method, pasteurization, and other methods. The global viral inactivation market was valued at USD 320.5 Million in 2016. This market is expected to grow at a CAGR of 12.3% to reach USD 573.0 Million in 2021.
- Published: June 2016
- Price: $ 4950
- TOC Available:
Virus Filtration Market by Product (Kits & Reagents, Systems, Services), Application (Biologics (Vaccine & Therapeutics, Blood, Tissues, Stem Cells), Devices, Air, Water Purification), End User (Biopharmaceutical, CROs, Research)

The global virus filtration market size is projected to grow at a CAGR of 12.3%. Virus filtration is an important operation in the pharmaceutical industry, as it not only ensures if the products are adequately purified and fit for consumption, but also helps to optimize process economics and prevent loss of valuable product.
- Published: April 2016
- Price: $ 4950
- TOC Available:
Business Model Analysis in Antimicrobial Coatings for Medical Devices – Key Players (Specialty Coatings Systems, Inc. (SCS), Royal DSM, Hydromer, Inc., PPG Industries, Inc., and BASF SE)

Medical devices are made of metals, such as stainless steel, aluminum, and ceramic. Many of these materials are not compatible with body tissues and fluids and can cause complications such as infections and blood clots. According to the Centers for Disease Control and Prevention (CDC), around 2,000,000 patients contract hospital-acquired infections (HAIs) every year in the U.S., resulting in 100,000 deaths; HAIs cost the U.S. healthcare system an estimated USD 45 billion annually. In addition, according to the European Centre for Disease, around 4,131,000 patients suffer from healthcare-associated infections every year in Europe. Rise in incidence of HAIs is a major challenge for healthcare providers; therefore, antimicrobial coatings have gained importance in recent years.
- Published: February 2016
- Price: $ 4950
- TOC Available:
Knock out Mouse Model Market Pricing Analysis – by Indication, Mouse type, End users, Discounting, Corporate Agreements, Economic Model of Demand and Supply, Physiological Characteristics, Business Models, and Stakeholder Analysis

Mice models are indispensable tools in research activities with their capability to elucidate human disease processes, due to striking similarities between the anatomy, physiology, and genetics of humans and mice. These advantages promote scientific discovery, understanding of the functions of individual genes, mechanisms of different diseases, and the effectiveness and toxicities of various drug molecules. Mice models are the most popularly used animal models due to their small size, short generation time, accelerated lifespan, low cost, and requirement of less space. These factors help in accelerating the research and development of drug therapies.
- Published: February 2016
- Price: $ 4950
- TOC Available:
Electrophoresis Reagents Market by Product (Dyes (EtBr & SYBR) Gels (Polyacrylamide, Starch, & Agarose) Buffer (TBE & TAE)) by Application (Protein Analysis, DNA & RNA Analysis) by Technique (Gel & Capillary Electrophoresis)

The global electrophoresis reagents market is projected to grow at a CAGR of 5.4%. The electrophoresis reagents market witnessed substantial growth and rapid technological advancements in the past few years, which had a positive impact on the overall growth of the market. The advancements have allowed the electrophoresis technique to be used in many new applications.
- Published: February 2016
- Price: $ 4950
- TOC Available:
qPCR Reagents Market by Detection (Dye-based, Probe-based), Packaging (qPCR Core Kits, Master Mixes), End User (Hospitals, Diagnostic Centers, Academia, Research Labs, CRO), Application (Diagnostic, Research, Forensic)

The global qPCR reagents market size is projected to grow at a CAGR of 7.7%. Market growth can be attributed to factors such as rising patient population base for infectious diseases & genetic disorders, coupled with growing geriatric population, technological advancements in the life sciences sector, increasing public-private investments, funds, and grants for PCR-based research, and the successful completion of the human genome project. However, technical limitations associated with qPCR are restraining the growth of this market.
- Published: January 2016
- Price: $ 4950
- TOC Available:
Human Insulin Market By Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes)

The global human insulin market size is projected to grow at a CAGR of 8.1%. Market growth can be attributed to factors such as growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements. However, stringent regulatory requirements for product approval are restraining the growth of this market.
- Published: December 2015
- Price: $ 4950
- TOC Available:
Protein Labeling Market by Product (Reagents, Kits, & Services), Labeling Method (In Vitro Labeling, In Vivo Labeling), Application (Cell-Based Assay, Fluorescence Microscopy, Immunological Technique), & Region - Global Forecast to 2020

The protein labeling market is expected to reach USD 1,894.5 Million by 2020 from USD 1,089.5 Million in 2015, at a CAGR of 11.7%. Protein labeling is carried out using labeling reagents and kits to label an antibody or other protein, to make a fluorescent probe, enzyme conjugate, biotinylated binding reagent, or iodine-labeled tracer for detecting proteins in tissues, cells, and biochemical assays.
- Published: December 2015
- Price: $ 4950
- TOC Available:
Nucleic Acid Labeling Market by Product (Reagents & Kits, Services), Applications, Labeling Techniques (PCR, Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, End Labeling), by Region - Global Forecast to 2020

The global nucleic acid labeling market is expected to USD 1,925.7 Million by 2020 from USD 1271.8 Million in 2015, at a CAGR of 8.65% between 2015 and 2020. Nucleic acid can be labeled using several different methods including incorporation of fluorescent tags, biotin, and enzymes. The labeled nucleic acid can be used for a variety of applications, including DNA sequencing, PCR, FISH, microarrays, blotting, and in situ hybridization. This market report studies the potential of reagents & kits and services for various applications by using PCR, nick translation, random primer labeling techniques.
- Published: December 2015
- Price: $ 4950
- TOC Available:
European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020

The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
- Published: October 2015
- Price: $ 4950
- TOC Available:
EDS, WDS, EBSD, Micro-XRF Instruments Market by Product, by Application (Energy, Defense, Metals, Medical, Research, Agriculture, Nanotechnology, Electronics, Biotechnology, Automotive, Pharmaceutical, Oil and Gas) - Global Forecasts to 2019

The global EDS, WDS, EBSD, and Micro-XRF instruments market is segmented on the basis of products, applications, and regions. Based on products, the market is categorized into EDS, WDS, EBSD, and Micro-XRF. The EDS segment accounted for a major share of the market, by product, in 2014. The global EDS, WDS, EBSD, and Micro-XRF instruments market is expected to reach USD 1,529.6 Million by 2019 from USD 403.6 Million in 2014, at a CAGR of 5.6% during the forecast period.
- Published: October 2015
- Price: $ 4950
- TOC Available:
Platelet Aggregation Devices Market by Product (Systems, Reagents, Consumables, Accessories), Application (Research, Diagnostic, CVD, Orthopedic, Trauma), End User (Hospitals, Diagnostic Laboratories, Academia, Blood Banks) - Global Forecasts to 2020

The global platelet aggregation devices market is poised to reach a value of 342.4 Million by 2020, growing at a CAGR of 21.0% from 2015 to 2020. Factors such as rising incidences of target diseases, rapid growth in the geriatric population across the globe, technological advancements in platelet aggregometers, and increasing number of industry-academia collaborations and clinical studies are fueling the growth of the global platelet aggregation devices market. However, procedural limitations, unfavorable healthcare reforms in the U.S., and dearth of well trained and skilled professionals are some of the key factors restraining the growth of this market.
- Published: August 2015
- Price: $ 4950
- TOC Available:
Expression Vectors Market by Host Type (Bacterial/E.Coli, Mammalian/CHO, Insect/Baculovirus, and Yeast), Application (Therapeutic, Research, and Industrial), End User (Pharmaceutical, Biotechnology, CROs & CMOs, and Academic Research) - Forecast to 2020

The expression vectors market is expected to reach $317.1 Million by 2020 from $242.7 Million in 2015, growing at a CAGR of 5.5% from 2015 to 2020. Major factors driving the growth of this market include the increasing demand of protein-based drugs (biologics); high prevalence of lifestyle diseases, infectious diseases, and genetic disorders; and increasing funding for protein research. On the other hand, high market consolidation, which increases entry barriers, and high cost of protein therapy are the major factors restraining the growth of this market.
- Published: June 2015
- Price: $ 4950
- TOC Available:
Protein Purification & Isolation Market by Technology (Precipitation, Dialysis, Electrophoresis, Western Blotting, Ion Exchange & Affinity Chromatography) by Product (Instruments, Kits, Reagents, Resins) by Application & End User - Global Forecast to 2020

Protein purification is a process for isolation of one or a more proteins from a complex mixture, usually consisting of cells or tissues. Protein purification is a necessary step in any protein study, and is performed after measuring the enzyme activity of the given sample through assay processes to confirm the presence of a protein or proteins of interest. The Global Protein Purification and Isolation Market Is Expected to Reach $11 Billion to $12 Billion by 2020
- Published: April 2015
- Price: $ 4950
- TOC Available:
Molecular Weight Marker Market by Products (DNA, RNA, Protein Ladders), Type (Prestained, Specialty), Application (PCR, Western Blotting, Gel Extraction), & End User (Academic Institutes, Pharmaceutical Companies, CRO) - Global Forecast to 2019

The global molecular weight marker market was valued at $265.36 million in 2014 and is poised to grow at a CAGR of 12.23 % between 2014 and 2019, to reach $472.47 million in 2019. Increased research and development spending by biotechnology and pharmaceutical companies, increasing public funding for life science research, and new innovations in genomics and proteomics research will drive the growth of the molecular weight markers market.
- Published: February 2015
- Price: $ 4950
- TOC Available:
Cell Line Development Market by Product (Equipment, Media and Reagents), Source, type & by Application ( Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, Drug Discovery) - Analysis & Global Forecast to 2019

The global cell line development market is expected to reach 3.96 billion by 2019 from $2.2 billion in 2014, and is expected to grow at a CAGR of 12.5% from 2014 to 2019. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America is expected to maintain its leadership position in the market in the coming years.
- Published: September 2014
- Price: $ 4950
- TOC Available:
Whole Exome Sequencing Market by Product [Systems, Kits (Library Preparation, Target Enrichment)], Services (Sequencing), Technology (Sequencing by Synthesis), & by Application (Cancer, Monogenic disorders) - Global Forecast to 2018

This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to maintain its leadership in the market in the coming years. Growth in the North American market is likely to be driven by factors such as the increasing use of exome sequencing in rare disease research, increased government funding, and large number of sequencing-related conferences and annual meetings hosted by the U.S.
- Published: August 2014
- Price: $ 4950
- TOC Available:
Biotechnology Reagents Market by Technology (PCR, Cell Culture, Expression & Transfection, Chromatography, Mass Spectrometry, Electrophoresis, & Flow Cytometry), Applications (Protein Purification, Gene Expression, DNA & RNA Analysis, & Drug Testing) and End-Users - Current Trends, Opportunities and Global Forecasts to 2016

Biotechnology reagents are the substances or compounds used to detect or synthesize another substance in order to provide a test reading. These reagents are used in the field of research, diagnosis, bioscience, and education.
- Published: July 2012
- Price: $ 4950
- TOC Available: